Dr. Michael A. Schwartz, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Rutgers New Jersey Medical School (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 621
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: Rutgers New Jersey Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
FL license ME00061671 -
Specialist
FL license ME00061671
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bethesda Hospital East Boynton Beach, FL
- Mount Sinai Medical Center of Florida, Inc Miami Beach, FL
Medical groups
- Physician Practices of Msmc LLC (181 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 621
- Services billed
- 2,912
- Patients’ average age
- 78
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 1,308 | 456 |
| Established patient office or other outpatient visit, 30-39 minutes | 423 | 245 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 118 | 30 |
| New patient office or other outpatient visit, 45-59 minutes | 111 | 111 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 61 | 46 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Miami Beach, FL | 117 |
| Revlimid (lenalidomide) | 94 |
| Tamoxifen Citrate Other prescribers in Miami Beach, FL | 72 |
| Imbruvica (ibrutinib) | 62 |
| Acyclovir Other prescribers in Miami Beach, FL | 53 |
| Prednisone Other prescribers in Miami Beach, FL | 46 |
| Hydroxyurea Other prescribers in Miami Beach, FL | 46 |
| Abiraterone Acetate | 40 |
| Jakafi (ruxolitinib phosphate) | 38 |
| Calquence (acalabrutinib maleate) | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 57 companies reported 304 payments worth $6,704 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $555 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $439 |
| Celgene Corporation | $431 |
| Pfizer Inc. | $417 |
| Janssen Biotech, Inc. | $400 |
| AbbVie Inc. | $287 |
| Incyte Corporation | $286 |
| Gilead Sciences, Inc. | $277 |
| Food and Beverage | $6,664 |
|---|---|
| Education | $40.22 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc Jul 24, 2025 | Education in-kind | $15.99 |
| Legend Biotech USA Inc. Dec 12, 2025 | Education CARVYKTI · Oncology · in-kind | $15.99 |
| Janssen Pharmaceuticals, Inc Aug 15, 2025 | Education in-kind | $8.24 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $18,127 in research payments for these studies, mostly to the institutions running them.
- The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc. - Single agent GDC 9545 vs endocrine monotherapy adjuvant treatment in HR eBC
Genentech, Inc. - Pallaspalbociclib collaborative adjuvant studya randomized phase iii trial of palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hr or HER2 early breast cancer WI…
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.